Wells Fargo
JUNO

Wells Fargo’s Juno Therapeutics, Inc. JUNO Stock Holding History

Wells Fargo’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-77,286
Closed -$3.53M – 6754
2017
Q4 		$3.53M Sell
77,286
-1,397
-2% -$69.7K ﹤0.01% 2895
2017
Q3 		$3.53M Buy
78,683
+6,934
+10% +$236K ﹤0.01% 2827
2017
Q2 		$2.14M Sell
71,749
-49,643
-41% -$1.22M ﹤0.01% 3164
2017
Q1 		$2.69M Buy
121,392
+85,516
+238% +$1.83M ﹤0.01% 2947
2016
Q4 		$676K Buy
35,876
+15,584
+77% +$381K ﹤0.01% 3996
2016
Q3 		$609K Buy
20,292
+5,715
+39% +$178K ﹤0.01% 3838
2016
Q2 		$560K Buy
14,577
+3,700
+34% +$154K ﹤0.01% 3846
2016
Q1 		$414K Sell
10,877
-6,545
-38% -$228K ﹤0.01% 3989
2015
Q4 		$767K Sell
17,422
-16,112
-48% -$799K ﹤0.01% 3647
2015
Q3 		$1.36M Buy
33,534
+23,795
+244% +$1.04M ﹤0.01% 3282
2015
Q2 		$520K Buy
9,739
+3,476
+56% +$184K ﹤0.01% 4065
2015
Q1 		$380K Sell
6,263
-4,584
-42% -$222K ﹤0.01% 4109
2014
Q4 		$566K Buy
+10,847
New +$485K ﹤0.01% 3884

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Wells Fargo's JUNO Position: Q1 2018 in Review

Wells Fargo sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 77,286 shares — an estimated $3.53M sold.

Wells Fargo first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $3.53M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Wells Fargo reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Wells Fargo sold 77,286 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $3.53M.
  • Wells Fargo first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Wells Fargo's Juno Therapeutics, Inc. position peaked at $3.53M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Wells Fargo's 13F filing for Q1 2018, filed 2 May 2018.